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Aim To determine the levels of circulating soluble recep-
tor for advanced glycation end products (sRAGE), as a bio-
marker of risk of metabolic syndrome and cardiovascular 
disease development in centrally obese (CO) women con-
sidered metabolically healthy (COH) in comparison with 
those metabolically unhealthy (COU).
Methods 47 lean healthy, 17 COH (presenting waist-to-
height ratio ≥0.5 but not elevated blood pressure, athero-
genic lipid profile, and insulin resistance), and 50 COU (CO 
presenting ≥2 risk factors) women aged 40-45 years were 
included. Anthropometric characteristics, blood chemistry 
and hematology data, adipokines, markers of inflamma-
tion, sRAGE, soluble vascular adhesion protein-1 (sVAP-1), 
and the activity of semicarbazide sensitive amine oxidase 
(SSAO) were determined.
Results Central obesity associated with low sRAGE levels 
(lean healthy: 1503 ± 633 pg/mL; COH: 1103 ± 339 pg/mL, 
P < 0.05; COU: 1106 ± 367 ng/mL, P < 0.0.1), hyperleptine-
mia, and elevated markers of inflammation irrespective of 
the presence or absence of cardiometabolic risk factors. 
COU women presented high adiponectin levels. SVAP-1 
concentrations and the activity of SSAO were similar in all 
3 groups.
Conclusion COH women present abnormalities in non-
standard markers of cardiometabolic risk (sRAGE, leptin, 
high sensitive C-reactive protein), supporting the view 
that there is no healthy pattern of obesity. The clinical im-
pact of our findings for future prognosis of metabolically 
healthy obese subjects remains to be elucidated in longi-
tudinal studies.
Association between 
metabolically healthy central 
obesity in women and levels of 
soluble receptor for advanced 
glycation end products, 
soluble vascular adhesion 
protein-1, and the activity of 
semicarbazide-sensitive amine 
oxidase
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Advanced glycation end products (AGEs) are adducts of 
reducing sugars or reactive aldehydes to proteins, lipo-
proteins or DNA. AGEs are formed in vivo spontaneously 
and mainly non-enzymatically in tissues and body fluids. 
Their excessive accumulation exerts negative health ef-
fects through modification of the structure and function 
of proteins or interaction with their specific cell surface 
receptor for AGEs – RAGE (1). AGE/RAGE interaction acti-
vates the nuclear factor kappa-B and other downstream 
pathways, resulting in production of reactive oxygen spe-
cies and pro-diabetic, pro-inflammatory, pro-thrombot-
ic, and pro-atherogenic responses (1). Circulating solu-
ble RAGEs (sRAGE) comprise the endogenous secretory 
RAGE (esRAGE, an alternatively spliced variant of RAGE) 
and a proteolytically (by a disintegrin and metallopro-
teinase-10 [ADAM10] and a matrix metalloproteinase-9 
[MMP-9]) cleaved form of the cell surface receptor (2,3). 
sRAGE levels are increased in chronic renal disease and 
diabetes, but low level of circulating sRAGE is considered 
a reliable biomarker for other diseases, such as metabolic 
syndrome and its components, atherosclerosis, coronary 
heart disease, and other conditions (4-6).
While majority of studies in subjects without diabetes re-
ported an inverse relationship between sRAGE and mea-
sures of adiposity (4,6-9), other studies revealed no sig-
nificant association (10,11). We speculated whether this 
discrepancy in findings might be explained by obese 
metabolically healthy phenotype, ie, obese subjects 
without increased blood pressure, atherogenic lipid pro-
file, and insulin resistance (12). We investigated whether 
centrally obese metabolically healthy women presented 
higher sRAGE levels than their centrally obese metaboli-
cally unhealthy counterparts. We also evaluated the lev-
els of soluble vascular adhesion protein-1 (sVAP-1) and its 
semicarbazide-sensitive amino oxidase (SSAO) activity. 
Both, RAGE and VAP-1 are cleaved from the cell surface 
by MMP-9 (3,13). SSAO converts less toxic primary amines 
into toxic reactive aldehydes – precursors of AGEs (14). 
Methylglyoxal-derived AGEs, such as hydroimidazolones 
and Nε-(carboxyethyl)lysine, are RAGE ligands (15). Thus, 
we anticipated that there might be a functional link be-
tween sRAGE and SSAO/sVAP-1.
 
SubjeCTS and MeThodS
This cross-sectional study was conducted in accordance 
to the principles of the Declaration of Helsinki. All subjects 
signed an informed consent to participate.
Subjects
Women were recruited via general practitioners or adver-
tisements posted in busy locations. Inclusion criteria were 
age between 40 and 45 years and stable physical condi-
tion. Exclusion criteria were any acute and chronic illness, 
particularly diabetes mellitus, cardiovascular diseases or 
cancer, unstable physical condition, disabilities, consump-
tion of >50 units of alcohol/week, any body weight lower-
ing regimen, pregnancy, and breast-feeding.
Of 190 recruited women, 6 were initially excluded for fast-
ing plasma glucose (FPG)>6.9 mmol/L (n = 4) and incom-
plete data for unequivocal determination of risk factors 
(n = 2). Of the remaining 184 women classified for presence 
of cardiometabolic risk factors, 88 were lean, ie, presented 
waist-to-height ratio (WHtR)<0.5. Forty-seven of them were 
lean healthy (LH), and 41 presented ≥1 risk factors, thus 
they were not included into the analysis. Ninety-six wom-
en were centrally obese. Seventeen were centrally obese 
healthy (COH), and 50 women were obese unhealthy wom-
en (COU). The remaining 29 centrally obese women present-
ed only 1 additional risk factor, thus they were not included 
into the analysis. The remaining 184 women were catego-
rized according to the presence of four cardiometabolic 
risk factors including central obesity, increased blood pres-
sure (BP), increased atherogenic risk, and insulin resistance. 
Central obesity was defined as WHtR≥0.5 (16); increased 
blood pressure as systolic BP≥130 mm Hg and/or diastolic 
BP≥85 mm Hg; increased atherogenic risk as atherogenic 
index of plasma ((AIP) = log(triacylglycerols/high-density li-
poprotein cholesterol))≥0.11 (17); and insulin resistance 
as quantitative insulin sensitivity check index (QUICKI = 1/
(log10(18.82xfasting plasma glucose)+log10 fasting plasma 
insulin))≤0.320 (corresponding to 25th percentile in the 
cohort). Thereafter, 3 groups were selected for this analysis 
as follows: LH women without any of the four risk factors 
(n = 47); COH women with no other risk factor except central 
obesity (n = 17); and COU women presenting with addition-
al ≥2 risk factors (n = 50). None of the included women was 
treated with antihypertensive and/or lipid lowering drugs.
Methods
Body weight was measured using calibrated electronic 
balance, height using extendable stadiometer, and waist 
circumference using flexible inelastic belt-type tape. BP 
and heart rate were measured using digital sphygmoma-
nometer at forearm in sitting position after 10-minute 
rest, and the mean value of the last 2 out of 3 mea-
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surements was recorded. Measurements were performed 
in the morning hours at the outpatient department.
Blood was taken from antecubital vein after overnight fast-
ing. Standard blood chemistry (FPG, lipid profile, creatinine, 
uric acid, albumin; Vitros 250 analyzer, Johnson&Johnson, 
Rochester, NY, USA) and blood count (Sysmex K-20 ana-
lyzer, TOA Medical Electronics, Kobe, Japan) were analyzed 
immediately. Plasma samples were stored at -80°C for spe-
cial analyses. Fasting plasma insulin (FPI) concentration was 
analyzed using a commercial radioimmunoassay (Immuno-
tech, Prague, Czech Republic). Commercial ELISA sets were 
used according to manufacturers’ instructions to determine 
high sensitive C-reactive protein (hsCRP, Immundiagnostik 
AG, Bensheim, Germany), sVAP-1 (eBioscience, Vienna Aus-
tria), adiponectin, leptin, and sRAGE (all R&D Systems, Min-
neapolis, MN, USA). SRAGE ELISA assay used in our study 
determines all circulating sRAGE splice variants. Advanced 
glycation end products-associated fluorescence of plasma 
(AGE-Fl) and advanced oxidation protein products (AOPPs) 
were determined as described previously (10). SSAO activity 
in plasma was determined radiometrically by liquid scintilla-
tion counting as described previously (18). The enzyme ac-
tivity was expressed as nmol of benzaldehyde formed by 1 
mg plasma protein in 1 h at 37°C (nmol mg-1 h-1).
Body mass index (BMI), waist-to-height ratio, quantitative in-
sulin sensitivity check index, atherogenic index of plasma, and 
glomerular filtration rate (eGFR; according to (19)) were cal-
culated. AGE-associated fluorescence of plasma and AOPPs 
were expressed as their ratio to plasma albumin (Alb).
Statistical analysis
Normality of data distribution and equality of variances 
were tested with Kolmogorov-Smirnov and Levene’s test, 
respectively. Data fitting to normal distribution are given as 
mean ± standard deviation (SD) and were compared using 
one-way analysis of variance (ANOVA) with post-hoc Schef-
fe’s test with correction of significance level for multiple com-
parisons. Skewed data are given as median and interquartile 
range. These groups were compared using Kruskal-Wallis 
test with subsequent Dunn’s post-hoc test with correction 
of significance level for multiple comparisons. Spearman or 
Pearson correlation coefficients (as appropriate) between 
sRAGE, sVAP-1 or SSAO activity and anthropometric, clini-
cal, and laboratory variables were calculated. To uncover 
the independent variables with class discriminating ability, 
an orthogonal partial least squares discriminant analysis 
(OPLS-DA) was performed using Simca v.13 software 
(Umea, Sweden). Age, height, heart rate, eGFR, white blood 
cell (WBC), red blood cell (RBC), and platelet counts, albu-
min, uric acid, hsCRP, adiponectin, leptin, sRAGE and sVAP-1 
concentrations, SSAO activity, AGE/Alb, and AOPP/Alb levels 
were entered as predictors. Variable of importance for the 
projection (VIP) value ≥1 was considered significant.
To assess which independent variables were significant 
predictors to selected dependent variables, a multivariate 
regression was performed using the general linear model 
(GLM). For sRAGE as dependent variable, those indepen-
dent variables were entered as covariates, which showed 
significant association to sRAGE in simple regression analy-
ses, ie, WHtR, SBP, DBP, QUICKI, AIP, eGFR, uric acid, ln hsCRP, 
ln adiponectin, ln leptin, AGE/Alb, ln AOPP/Alb, plate-
let count, SSAO activity, and sVAP-1. WHtR, ln hsCRP, and 
sRAGE were entered as independent predictors of SSAO 
activity. P < 0.05 was considered significant. Statistical anal-
yses were performed using SPSS version 22 (SPSS Inc., Chi-
cago, IL, USA) and GraphPad Prism v. 6.0 (California, USA).
The statistical power of the study was determined using 
the post-hoc power test. With 2-sided confidence interval 
of 95%, the power of comparison between 47 lean healthy 
subjects presenting mean sRAGE concentration of 1503 
pg/mL with SD of 633 pg/mL and 17 COH subjects with 
sRAGE levels of 1103 ± 339 pg/mL was 89.9%.
ReSulTS
COU women were significantly older in comparison with 
their lean healthy counterparts (Table 1), however, the age-
difference of 9.6 months in mean cannot be considered in 
40-year-olds as clinically significant. Both groups of cen-
trally obese women tended to be shorter in comparison 
with lean healthy subjects, however, post-hoc Scheffe’s test 
failed to identify significant between group differences. In 
comparison with lean healthy subjects, COH women pre-
sented with significantly higher FPG, and lower insulin sen-
sitivity (within the insulin sensitive range, ie, QUICKI≥0.320). 
COH and COU groups has similar characteristics of general 
and central obesity.
Standard blood chemistry and red blood cells and 
platelets counts
No significant differences in albuminemia were observed 
between the groups. COU women presented mildly ele-
vated uric acid concentrations, significantly higher in com-
parison with lean healthy subjects. Markers of renal func-
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tion (eg, plasma creatinine concentration and eGFR) did 
not differ significantly between the groups (Table 1). COU 
women had higher red blood cells and platelets counts in 
comparison with lean healthy subjects.
Inflammatory markers
Both groups of centrally obese women presented higher 
hsCRP concentrations in comparison with their lean healthy 
Table 1. anthropometric characteristics, blood chemistry, and hematology data of women included in the study
lh (n = 47) Coh (n = 17) Cou (n = 50) P
Age (years)  42.0 (40.0; 43.0)  42.0 (41.5; 43.0)  42.0 (41.0; 44.0)* 0.015
Height (cm) 168.1 ± 6.9 163.4 ± 6.6 165.3 ± 7.7 0.037†
Weight (kg)  63.2 ± 8.0  82.3 ± 16.8§  89.4 ± 17.4§ <0.001
Waist (cm)  74.3 ± 6.2  94.1 ± 11.9§  97.7 ± 9.2§ <0.001
BMI (kg/m2)  22.3 ± 2.3  30.7 ± 5.3§  32.5 ± 4.7§ <0.001
Waist/height   0.44 ± 0.03   0.58 ± 0.07§   0.59 ± 0.05§ <0.001
SBP (mmHg) 116 ± 7 120 ± 6 139 ± 13§,¶ <0.001
DBP (mmHg)  74 ± 5  77 ± 5  92 ± 8§,¶ <0.001
Heart rate (x/min)  71 ± 9  72 ± 10  80 ± 12§,+ <0.001
FPG (mmol/L)   5.0 ± 0.4   5.3 ± 0.4*   5.6 ± 0.5§ <0.001
FPI (μIU/ml)   6.3 (5.5; 8.5)   8.1 (6.8; 10.6)  14.8 (10.2; 18.3)§,¶ <0.001
QUICKI   0.361 ± 0.020   0.344 ± 0.014*   0.318 ± 0.020§,¶ <0.001
Albumin (g/L)  45 ± 3  45 ± 5  44 ± 4 0.619
Cholesterol (mmol/L)   4.9 ± 0.9   5.5 ± 0.9*   5.4 ± 1.0 0.028†
HDL-C (mmol/L)   1.5 (1.4; 1.9)   1.5 (1.4; 1.8)   1.2 (1.0; 1.4)§,¶ <0.001
LDL-C (mmol/L)   2.9 ± 0.7   3.4 ± 0.8   3.3 ± 0.9* 0.014
VLDL-C (mmol/L)   0.4 (0.3; 0.5)   0.5 (0.4; 0.6)   0.8 (0.6; 1.0)§,¶ <0.001
TAG (mmol/L)   0.8 (0.7; 1.1)   1.1 (0.9; 1.3)   1.8 (1.3; 2.3)§,¶ <0.001
AIP   -0.29 ± 0.18   -0.17 ± 0.15   0.18 ± 0.23§,¶ <0.001
Uric acid (mmol/L) 211 ± 53 244 ± 63 280 ± 62§ <0.001
Creatinine (μmol/L)  73 ± 15  70 ± 9  70 ± 12 0.622
eGFR (ml s-1 (1.73m2)-1)   1.6 ± 0.4   1.6 ± 0.2   1.6 ± 0.3 0.798
WBC (x*109/L)   6.2 ± 1.4   6.6 ± 1.4   7.7 ± 2.1§ <0.001
RBC (x*1012/L)   4.5 ± 0.4   4.5 ± 0.3   4.7 ± 0.4* 0.013
Plt (x*109/L) 241 ± 67 258 ± 65 297 ± 64§ <0.001
hsCRP (mg/L)   3.1 (2.0; 4.1)   4.5 (3.3; 8.1)‡   5.7 (4.2; 9.2)§ <0.001
Adiponectin (ng/mL)  14.5 (9.8; 20.4)  12.8 (9.7; 18.6)   8.6 (5.6; 10.3)§,II <0.001
Leptin (ng/mL)  11.4 (6.4; 19.3)  38.5 (18.0; 66.6)§  44.0 (28.0; 57.0)§ <0.001
AOPP/Alb   1.2 (1.0; 1.4)   1.1 (0.9; 1.9)   2.7 (1.7; 4.4)§,¶ <0.001
AGE-Fl/Alb  55.4 ± 14.0  55.6 ± 15.3  52.3 ± 14.8 0.531
Presence of cardiometabolic risk factors was classified as follows: central obesity: WhtR≥0.5; elevated bP: systolic bP (SbP)≥130 mm hg and/or 
diastolic bP (dbP)≥ 85 mm hg; increased atherogenic risk: aIP = log(TaG/hdl)≥0.11 (17); insulin resistance: QuICKI≤0.320 (corresponding to 25th per-
centile in the cohort) . lean healthy (lh) women did not present any risk factor; centrally obese healthy (Coh) women did not present any other risk 
factor except for central obesity; centrally obese unhealthy (Cou) women presented ≥2 additional risk factors except for central obesity; bMI: body 
mass index; SbP: systolic blood pressure; dbP: diastolic blood pressure; FPG: fasting plasma glucose; FPI: fasting plasma insulin; QuICKI: quantitative 
insulin sensitivity check index; hdl-C: high density lipoprotein cholesterol; ldl-C: low density lipoprotein cholesterol; Vldl-C: very low density lipo-
protein cholesterol; TaG: triacylglycerols; aIP: atherogenic index of plasma; eGFR: estimated glomerular filtration rate (abbreviated MdRd formula); 
WbC: leukocyte count; RbC: erythrocyte count; Plt: platelet count; hsCRP: high sensitive C-reactive protein; aoPP/alb: advanced oxidation protein 
products corrected for plasma albumin; aGe-Fl/alb: advanced glycation end products-associated fluorescence of plasma corrected for plasma albu-
min; au: arbitrary units; data presented as mean ± Sd or as median and interquartile range; normally distributed data were compared using one-way 
analysis of variance with Scheffe’s post-hoc test with correction for multiple comparisons; skewed data were compared using Kruskal-Wallis test with 
post-hoc dunnet’s test with correction for multiple comparisons.
*P > 0.05 vs lean healthy.
†Scheffe’s test did not indicate significance between the groups
‡P > 0.01 vs lean healthy.
§P > 0.001 vs lean healthy.
IIP > 0.01 vs centrally obese healthy.
¶P > 0.001 vs centrally obese healthy.
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counterparts. COU women had higher WBC counts in com-
parison with COH and lean healthy women (Table 1).
adipokines
COU women presented lower adiponectin concentrations 
in comparison lean healthy and COH subjects, while leptin 
concentrations were similarly increased in both groups of 
centrally obese women if compared with those lean and 
healthy (Table 1).
advanced glycation end products and advanced 
oxidation protein products
AGE-Fl/Alb levels did not differ significantly between the 
groups. COU women presented higher AOPP/Alb levels in 
comparison with lean healthy and COH groups (Table 1).
sRaGe, sVaP-1 concentration and SSao activity
Both groups of centrally obese women presented low-
er sRAGE concentrations in comparison with their lean 
healthy counterparts (LH: 1370 (1011; 1765) pg/mL; COH: 
969 (815; 1442) pg/mL; COU: 1062 (832; 1266) pg/mL; 
P < 0.001). (Figure 1). SVAP-1 concentration (LH: 252 (198; 
303) ng/mL; COH: 285 (207; 303) ng/mL; COU: 248 (209; 
309) ng/mL; P = 0.596) and SSAO activity (LH: 99 (82; 123) 
nmol mg-1 h-1; COH: 96 (85; 108) nmol mg-1 h-1; COU: 97 (82; 
FIGuRe 1. activity of semicarbazide-sensitive amine oxidase, 
plasma soluble vascular adhesion protein-1 and soluble 
receptor for advanced glycation end products levels in lean 
healthy, centrally obese healthy and centrally obese unhealthy 
women. SSao: activity of semicarbazide-sensitive amine 
oxidase; sVaP-1: soluble vascular adhesion protein-1; sRaGe: 
soluble receptor for advanced glycation end products; lh: lean 
healthy; Coh: centrally obese healthy; Cou: centrally obese 
unhealthy women. data presented as minimum, first quartile, 
median, third quartile and maximum. Kruskal-Wallis test with 
subsequent dunn’s test with correction of P for multiple com-
parisons were used for statistical comparison. Significant dif-
ferences between the groups are shown. *P < 0.05; **P < 0.01.
FIGuRe 2. Score scatter plot from oPlS-da model of lean healthy women, centrally obese healthy, and centrally obese unhealthy 
women. lh: lean healthy women, (gray circles); Coh: centrally obese healthy women, (squares); Cou: centrally obese unhealthy 
women, black triangles). Scores are orthogonal ( = completely independent from each other), representing new variables summa-
rizing the input of all determined variables (herein age, height, heart rate, eGFR, WbC, RbC and platelet counts, albumin, uric acid, 
hsCRP, adiponectin, leptin, sRaGe and sVaP-1 concentrations, SSao activity, aGe/alb and aoPP/alb levels) so that one score vector 
corresponds to one subject, having its own score vector. observations situated outside hotelling’s T2 tolerance ellipse are mild 
outliers. Model reveals that Coh women scatter between the lh and Coh women, while the two latter groups are well separated 
(separation in direction of x-axis). Separation in direction of y-axis represents within group variability.
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114) nmol mg-1 h-1; P = 0.627) did not differ significantly be-
tween the groups (Figure 1).
Multivariate analysis.
OPLS-DA confirmed that COH women presented inter-
mediate phenotype: COH subjects projected scattered 
among relatively well separated groups of lean healthy 
and COU women (Figure 2). Model explained 53% of be-
tween-groups variation. Leptin, hsCRP, WBC count, UA, 
sRAGE, adiponectin, sVAP-1 and heart rate were selected 
as independent predictors contributing significantly to 
separation between the groups (VIP values 1.53-to-1.00), 
(loading scatter plot and VIP plot given in supplementary 
material).
sRaGe
sRAGE levels correlated significantly and inversely with 
body weight, waist circumference, BMI, WHtR, SBP, DBP, 
FPG, FPI, LDL-C, VLDL-C, TAG, AIP, uric acid, eGFR, platelet 
Table 2. Pearson or Spearman’s correlation coefficients 
between concentration of soluble receptor for advanced gly-
cation end products (sRaGe) and anthropometric, clinical, and 
laboratory variables in women included in the study *
R P
Weight -0.357 <0.001
Waist -0.439 <0.001
BMI -0.438 <0.001
Waist/height -0.471 <0.001
SBP -0.206 0.029
DBP -0.235 0.013
FPG -0.280 0.003
FPI -0.321 0.001
QUICKI 0.340 <0.001
LDL-C -0.195 0.040
VLDL-C -0.239 0.012
TAG -0.213 0.024
AIP -0.204 0.031
Uric acid -0.242 0.010
Creatinine 0.245 0.009
eGFR -0.230 0.015
Plt -0.287 0.002
hsCRP -0.348 <0.001
Adiponectin 0.199 0.035
Leptin -0.308 0.001
SSAO 0.381 <0.001
AGE/Alb 0.197 0.037
*abbreviations – bMI: body mass index; SbP: systolic blood pressure; 
dbP: diastolic blood pressure; QuICKI: quantitative insulin sensitivity 
check index; hdl-C: high density lipoprotein cholesterol; ldl-C: low 
density lipoprotein cholesterol; Vldl-C: very low density lipoprotein 
cholesterol; TaG: triacylglycerols; aIP: atherogenic index of plasma; 
eGFR: estimated glomerular filtration rate (abbreviated MdRd 
formula); WbC: leukocyte count; RbC: erythrocyte count; Plt: platelet 
count; hsCRP: high sensitive C-reactive protein; SSao: activity of semi-
carbazide-sensitive amine oxidase; sVaP-1: soluble vascular adhesion 
protein-1; aoPP/alb: advanced oxidation protein products corrected 
for plasma albumin; aGe-Fl/alb: advanced glycation end products-as-
sociated fluorescence of plasma corrected for plasma albumin; italics: 
Spearman’s correlation coefficient; relationship between sRaGe and 
cholesterol or hdl-C concentrations, WbC or RbC count, and aGe-Fl/
alb were not significant
FIGuRe 3. Correlation between activity of semicarbazide-
sensitive amine oxidase and soluble receptor for advanced 
glycation end products levels in lean healthy, centrally obese 
healthy and unhealthy women. SSao: activity of semicar-
bazide-sensitive amine oxidase; sRaGe: soluble receptor for 
advanced glycation end products; lh: lean healthy; Coh: cen-
trally obese healthy; Cou: centrally obese unhealthy women.
FIGuRe 4. Correlation between concentration of soluble 
vascular adhesion protein-1 and soluble receptor for advanced 
glycation end products levels in lean healthy, centrally obese 
healthy and unhealthy women. SSao: activity of semicar-
bazide-sensitive amine oxidase; sRaGe: soluble receptor for 
advanced glycation end products; lh: lean healthy; Coh: cen-
trally obese healthy; Cou: centrally obese unhealthy women.
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count, hsCRP, and leptin (Table 2). Significant positive re-
lationship of sRAGE with insulin sensitivity, creatinine, ad-
iponectin, and AGE-Fl/Alb has been revealed (Table 2). 
sRAGE showed a significant positive relationship to SSAO 
activity (Figure 3), while relationship between sRAGE and 
sVAP-1 was insignificant (Figure 4). GLM selected WHtR 
(P < 0.001; β: -3234; SE:1023), platelet count (P = 0.018; β: 
-1.60; SE: 0.67), and SSAO activity (P = 0.011; β: 6.62; SE: 
2.56) as independent significant predictors of sRAGE levels 
(overall model P < 0.001; R2: 0.31).
SSao activity and sVaP-1
Except for significant positive relationship with sRAGE (Fig-
ure 3), SSAO activity correlated positively with sVAP-1 lev-
els (Figure 5). It also showed significant inverse relationship 
with BMI (r = -0.190, P = 0.047), WHtR (r = -0.214, P = 0.025), 
and ln hsCRP (r = -0.235, P = 0.014). GLM selected only 
sRAGE (P < 0.001; β: 0.017; SE: 0.005) as independent sig-
nificant predictor of SSAO activity (overall model P < 0.001; 
R2: 0.14). Except for SSAO activity, sVAP-1 correlated signifi-
cantly only with erythrocytes count (r = 0.224, P = 0.021).
dISCuSSIon
To the best of our knowledge this is the first study inves-
tigating sRAGE levels, sVAP-1 and SSAO activity in lean vs 
metabolically healthy and unhealthy CO women. In con-
trast to our hypothesis, we revealed similar decline in 
sRAGE levels in COH and COU women. Moreover, our data 
show that central obesity is not associated with significant 
changes in SSAO activity/sVAP-1 levels, regardless of pres-
ence or absence of cardiovascular risk factors.
Obesity represents a key risk factor for development of 
metabolic syndrome, type 2 diabetes, cardiovascular dis-
eases, and certain types of cancer - all of which may lead to 
increased mortality. However, 10%-to-30% of obese indi-
viduals present phenotype free from metabolic abnormali-
ties (12). Thus, the proportion of COH women in our study 
(18%) corresponded with percentages reported for oth-
er populations (12). Metabolically healthy obesity (MHO) 
does not appear to be a benign condition: the prognosis 
in MHO individuals for cardiovascular disease is as poor 
as that in the metabolically unhealthy obese (MUO) (20). 
Although MHO phenotype carries less risk for type 2 dia-
betes when compared with MUO, the risk is greater than 
that in the metabolically healthy normal weight subjects 
(20,21). In contrast to MUO subjects MHO do not improve 
significantly their cardiometabolic risk upon weight loss in-
terventions (12).
MHO phenotype is generally defined as presence of obe-
sity (BMI<30.0 kg/m2, not taking into account fat distribu-
tion), accompanied with <3 cardiometabolic risk factors 
- elevated BP, TAG, and FPG levels, and decreased HDL-cho-
lesterol (12). However, central obesity, particularly if mea-
sured as WHtR, is a better prognostic marker of cardiomet-
abolic risk than BMI (22). Similarly, AIP is a better predictor 
of atherogenic risk than TAG and HDL-C levels evaluated 
separately (17). FPG might be maintained within the refer-
ence range on the account of hyperinsulinemia, thus FPG 
is not a reliable proxy of normal glucose homeostasis (12). 
Thus, we used strict criteria to define MHO phenotype, eg, 
centrally obese insulin sensitive subject not presenting in-
creased atherogenic risk and elevated BP. We are not aware 
of any study using zero cardiometabolic risk components 
to define MHO, and ≤1 additional criteria to obesity are also 
seldom used in comparison with 2 criteria (23). We showed 
that even under our strict classification COH women pres-
ent lower insulin sensitivity, elevated hsCRP and leptin lev-
els if compared with their lean healthy counterparts. MHO 
was also associated with higher total cholesterol levels, 
however, only tendency toward unfavorable lipid profile 
and AIP was observed. Moreover, COH women tended 
to present higher BP values, uric acid and AOPP/Alb lev-
els, leukocyte and platelet counts if compared with lean 
healthy subjects – variables which were significantly higher 
in COU women. Concurrent rise in hsCRP, leukocyte counts 
FIGuRe 5. Correlation between activity of semicarbazide-sen-
sitive amine oxidase and soluble vascular adhesion protein-1 
levels in lean healthy, centrally obese healthy and unhealthy 
women. SSao: activity of semicarbazide-sensitive amine 
oxidase; sVaP-1: soluble vascular adhesion protein-1; lh: lean 
healthy; Coh: centrally obese healthy; Cou: centrally obese 
unhealthy women.
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and AOPPs (myeloperoxidase reaction-derived products 
reflecting enhanced activation of phagocytes) (24) points 
to activation of microinflammation processes. On the oth-
er hand, COH women maintained their adiponectin levels 
despite marked hyperleptinemia – phenomenon reported 
previously, and potentially contributing to maintenance of 
insulin sensitivity in MHO phenotype (25).
SRAGE levels are similarly decreased in metabolically 
healthy and metabolically unhealthy centrally obese wom-
en. Although majority of studies in subjects without diabe-
tes (including pre-pubertal children and elderly subjects) 
report inverse relationship between measures of obesity 
and sRAGE levels (4,6-9), the data are equivocal (10,11). 
We did not confirm our hypothesis that this discrepancy 
might be on the account of MHO phenotype: COH and 
COU women who did not differ with regard to their mea-
sures of obesity displayed similar decline in sRAGE levels. 
Mechanisms leading to obesity-associated sRAGE decline 
remain unclear. In homeostasis tissue expression of RAGE 
is low, and increases with accumulation RAGE ligands (1). 
In obesity enhanced oxidative stress, microinflammation, 
and accumulation of lipophilic AGEs induce increased 
RAGE expression in adipose tissue (26). Thus, if sRAGE lev-
els mirror tissue RAGE expression, plasma sRAGE should 
be increased in obesity. In obese pre-pubertal children 
and adolescents esRAGE-to-sRAGE ratio remains constant 
(27,28). Thus, endogenous secretory and metalloproteinas-
es-shaded isoforms of sRAGE decline proportionally. While 
no data on ADAM10 expression or activity in obesity are 
available, plasma MMP-9 levels and its expression in fat tis-
sue of obese subjects are increased (29,30). However, com-
plex interaction of MMPs with their tissue inhibitors does 
not allow us to speculate whether shading of RAGE is di-
minished in obesity. Assumption that sRAGE may act as de-
coy trapping circulating AGEs seems unsubstantiated, as 
the levels of sRAGE are 3-orders of magnitude lower than 
even the concentrations of the most abundant plasma 
AGE – Nε-(carboxymethyl)lysine (CML) (31). Moreover, plas-
ma CML-to-sRAGE ratio remains constant with increasing 
number of metabolic syndrome risk factors (4). Circulating 
levels of hydroimidazolones which bind to RAGE with the 
highest affinity and specificity among all chemically de-
fined AGEs (15) are not increased in obesity (32). Howev-
er, another RAGE ligand – pro-inflammatory cytokine high 
mobility group protein box-1 (HMGB1), displaying 10-fold 
higher binding affinity to RAGE in comparison with AGEs, 
circulates in concentrations similar to those of sRAGE, and 
has been shown to be increased in obesity (33). HMGB1 is 
secreted by preadipocytes and controls inflammation (ie, 
the secretion of interleukine-6 and monocyte chemotactic 
protein-1) in adipose tissues through the binding to RAGE 
(34). In general population sRAGE independently and in-
versely associated with HMGB1 (35). Herein we showed 
negative relationship between inflammatory markers 
(hsCRP, AOPP/Alb) and sRAGE. Whether decreased sRAGE 
level in obesity reflects mainly the pro-inflammatory sta-
tus, particularly associated with high HMGB1 levels, re-
mains to be confirmed. In large community-based popula-
tion study in subjects without diabetes low levels of sRAGE 
were significantly associated with future risk of diabetes, 
coronary heart disease, and mortality (36). In healthy adult 
women lower sRAGE levels reflected accumulation of the 
epicardial visceral fat (9). Thus, low sRAGE levels associating 
with microinflammatory status suggest that despite an ab-
sence of standard cardiometabolic risk factors MHO wom-
en might be on increased risk to develop cardiometabolic 
disease in future. As sRAGE concentrations remain rela-
tively stable over years, it has been suggested that a single 
measure of circulating sRAGE may be sufficient for charac-
terizing long-term risk in the general population (37).
SSAO/sVAP-1 are not altered in metabolically healthy and 
unhealthy centrally obese women. VAP-1 represents a mol-
ecule with a dual action: as adhesion molecule it favors lym-
phocyte recruitment into site of inflammation; possessing 
enzyme activity of semicarbazide-sensitive amine oxidase 
(SSAO, EC 1.4.3.21) it converts primary amines into corre-
sponding aldehydes (eg, aminoacetone into methylglyox-
al), generating H2O2 and ammonia (14). Thus, as expected, 
sVAP-1 and plasma SSAO activity showed tight correlation 
in our study. The membrane form of SSAO/VAP-1, highly 
expressed in endothelial cells, regulates leukocyte traf-
ficking into site of inflammation (38). In obesity the mem-
brane-bound VAP-1 is abundantly expressed on white fat 
cells, and is supposed to contribute to adipogenesis and 
pathological energy metabolism (38). It has been suggest-
ed that in obesity VAP-1 remains in the membrane-bound 
form, with a concurrent decrease in the circulating sVAP-1 
concentration (39). On the other hand, a different study re-
ported an elevated plasma SSAO activity in morbidly obese 
patients (40); while in our study neither concentrations of 
sVAP-1, nor the plasma SSAO activity differed significantly 
between lean and centrally obese women, regardless of 
their phenotype. Clinical data on sVAP-1/SSAO in obesity 
are scares, with contradictory results, and require further 
aimed investigations.
Formation of AGEs is accelerated under conditions of 
enhanced oxidative stress such as obesity, and meth-
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ylglyoxal is considered to be the most potent glycation 
agent (26). Both, enhanced oxidative stress and methylg-
lyoxal may induce insulin resistance (41). Similarly to RAGE, 
VAP-1 is shaded by MMPs (13). Thus, we assumed that in 
obesity sRAGE, sVAP-1 levels and SSAO activity might as-
sociate. However, in contrast to sRAGE levels SSAO activ-
ity and sVAP-1 were not altered in centrally obese wom-
en. Obese individuals present approximately 35% higher 
plasma methylglyoxal levels in comparison with their lean 
counterparts (32), but circulating methylglyoxal levels 
show no significant relationship with measures of obe-
sity (42). Our data suggest that obesity-associated rise in 
methylglyoxal is not due to increase in SSAO activity. De-
spite its unchanged activity in obesity, SSAO showed posi-
tive relationship with sRAGE, and in multivariate analyses 
appeared as a significant independent predictor to sRAGE 
levels. Equivocal results of statistical analyses do not al-
low any speculation on potential interplay of RAGE/SSAO/
VAP-1 systems in central obesity – further studies are defi-
nitely needed.
The strengths of our study include recruitment of White 
Caucasian women of Middle European descent, without 
diabetes, of similar age, from geographically restricted area 
of South-Western Slovakia; strict criteria used to define 
MHO; determination of variety of non-standard cardiomet-
abolic risk markers; and complex statistical approach. The 
weaknesses of this study are largely related to its cross-sec-
tional design, not allowing elucidation of the causal rela-
tionships between circulating sRAGE, sVAP-1, SSAO activity 
and anthropometric, metabolic, and inflammatory vari-
ables, ie, issues better examined in a longitudinal study.
Conclusion
Our data suggest that by strict criteria classified central-
ly obese women present abnormalities in non-standard 
markers of cardiometabolic risk, emphasizing that there is 
no healthy pattern of obesity. The clinical impact of low 
sRAGE levels for future prognosis of metabolically healthy 
obese subjects, and potential interaction in RAGE/VAP-1/
SSAO axis in obesity-associated pathology remain to be 
elucidated in longitudinal studies.
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